Wells Fargo Raises Price Target on Intuitive Surgical to $630 From $549, Keeps Overweight Rating
Intuitive Surgical Analyst Ratings
Citi Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $640
Wells Fargo Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $630
Stifel Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $610
Intuitive Surgical Is Maintained at Buy by Stifel
Intuitive Surgical Analyst Ratings
Morgan Stanley Initiates Intuitive Surgical(ISRG.US) With Buy Rating, Announces Target Price $650
Intuitive Surgical (ISRG) Gets a Buy From Leerink Partners
BTIG Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $561
BTIG Adjusts Price Target on Intuitive Surgical to $561 From $535, Maintains Buy Rating
Intuitive Surgical Analyst Ratings
Erste Group Initiates Intuitive Surgical(ISRG.US) With Buy Rating
HSBC Raises Intuitive Surgical Price Target to $643 From $586
BofA Securities Maintains Intuitive Surgical(ISRG.US) With Buy Rating
Intuitive Surgical (ISRG) Gets a Buy From Bank of America Securities
BofA Securities Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $550
Argus Adjusts Price Target on Intuitive Surgical to $570 From $520
Morgan Stanley Maintains Intuitive Surgical(ISRG.US) With Hold Rating, Raises Target Price to $522
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)